No quarterly revenue total was found in Corbus Pharmaceuticals Holdings, Inc.'s SEC filings.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$29.6 million. As of Jun 30, 2026 it held $117.9 million in cash and investments and $4.3 million in total debt.
Revenue
—
Net income
$-35.04M
-98.4% vs year-ago quarter
Operating cash flow
$-29.63M
-78.5% vs year-ago quarter
Free cash flow
$-29.63M
-15.9% vs prior quarter
EPS
$-1.81
-25.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
19.34M
+57.8% vs year-ago quarter
Net cash
$113.68M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Norwood, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1595097
- Former names
- SAV Acquisition Corp (until Jan 10, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$36.2M | -$24.3M | -$22.0M | -$24.4M | -$19.2M |
| Net income | -$35.0M | -$23.0M | -$20.6M | -$23.3M | -$17.7M |
| Diluted EPS | -$1.81 | -$1.23 | -$1.25 | -$1.90 | -$1.44 |
| Operating cash flow | -$29.6M | -$25.6M | -$15.9M | -$15.6M | -$16.6M |
| Free cash flow | -$29.6M | -$25.6M | — | — | — |
| Total assets | $127.0M | $144.5M | $168.2M | $109.5M | $125.1M |
| Total liabilities | $24.7M | $18.1M | $20.7M | $17.4M | $14.1M |
| Stockholders' equity | $102.2M | $126.3M | $147.5M | $92.1M | $111.0M |
| Cash and investments | $117.9M | $138.2M | $163.3M | $104.0M | $116.6M |
| Total debt | $4.3M | $1.2M | $1.6M | $2.0M | $2.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 6, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 26, 2026 | May 26, 2026 |
All 808 Corbus Pharmaceuticals Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.